Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | DGKA | P23743 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2521742 | 0.87 | FAAH (0.38) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL2368458 | 0.85 | GAA (0.50) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL20511453 | 0.82 | — | — | |
| SCHEMBL11514649 | 0.80 | — | — | |
| SCHEMBL11040477 | 0.79 | FAAH (0.55) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL11041532 | 0.79 | FAAH (0.55) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL11037465 | 0.79 | FAAH (0.55) | MGAMGAASIMGAM2FAAH | |
| Butane SCHEMBL9065845 | 0.79 | FAAH (0.46) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL29046206 | 0.79 | FAAH (0.34) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL11599095 | 0.78 | DGKA (0.54) | FAAHCYP2C19L3MBTL1ALDH1A1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251158-A1 | FULLERENE THERAPIES FOR INFLAMMATION AND INHIBITION OF BUILD-UP OF ARTERIAL PLAQUE | LUNA INNOVATIONS INCORPORATED (US) | 2011-10-13 | — | — | US | disclosed |
| US-20050267102-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-01 | — | — | US | disclosed |
| EP-0923530-B1 | INHIBITION OF MATRIX METALLOPROTEASES BY SUBSTITUTED BIARYL OXOBUTYRIC ACIDS | BAYER AG (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6762184-B2 | RHEUMATIC DISEASES; ORAL ISEASES; VISION DEFECTS; ANTIINFLAMMATORY AGENTS | BAYER PHARMACEUTICALS CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-6500847-B2 | RHEUMATIC DISEASES; ORAL ISEASES; VISION DEFECTS; ANTIINFLAMMATORY AGENTS | BAYER CORPORATION | 2002-12-31 | — | — | US | disclosed |
| US-20020042417-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION | 2002-04-11 | — | — | US | disclosed |
| US-20020042418-A1 | Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acides | BAYER PHARMACEUTICALS CORPORATION | 2002-04-11 | — | — | US | disclosed |
| US-6225314-B1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER CORPORATION | 2001-05-01 | — | — | US | disclosed |
| US-5925637-A | ENZYME INHIBITORS AS ANTIARTHRITIC AGENTS OR CARDIOVASCULAR DISORDERS | BAYER CORPORATION (US) | 1999-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042417-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | ADAMTS5, ADAMTS1, MMP13 | MGAM 190/4885GAA 315/4885SI 121/4885 |
| US-20050267102-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | MMP20, ADAMTS5, MMP10 | MGAM 203/4885GAA 434/4885SI 137/4885 |
| US-20110251158-A1 | FULLERENE THERAPIES FOR INFLAMMATION AND INHIBITION OF BUILD-UP OF ARTERIAL PLAQUE | IL1B, IL1A, CD68 | MGAM 4348/4885GAA 2992/4885SI 4489/4885 |
| US-20020042418-A1 | Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acides | ADAMTS5, ADAMTS1, ADAMTS4 | MGAM 123/4885GAA 228/4885SI 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.